title: The alternative reading frame tumor suppressor antagonizes hypoxia-induced cancer cell migration via interaction with the COOH-terminal binding protein corepressor.
abstract: The alternative reading frame (ARF) tumor suppressor exerts both p53-dependent and p53-independent activities critical to the prevention of cancer in mice and humans. Recent evidence from mouse models suggests that when p53 is absent, further loss of ARF can widen the tumor spectrum, and potentiate invasion and metastasis. A major target of the p53-independent activity of ARF is the COOH-terminal binding protein (CtBP) family of metabolically regulated transcriptional corepressors, which are degraded upon acute exposure to the ARF protein. CtBPs are activated under conditions of metabolic stress, such as hypoxia, to repress epithelial and proapoptotic genes, and can mediate hypoxia-induced migration of cancer cells. The possibility that ARF could suppress tumor cell migration as part of its p53-independent activities was thus explored. Small-interfering RNA (siRNA)-mediated knockdown of ARF in human lung carcinoma cells led to increased cell migration, especially during hypoxia, and this effect was blocked by concomitant treatment with CtBP2 siRNA. Introduction of ARF into p53 and ARF-null human colon cancer cells inhibited hypoxia-induced migration. Furthermore, overexpression of CtBP2 in ARF-expressing cells enhanced cell migration, and an ARF mutant defective in CtBP-family binding was impaired in its ability to inhibit cell migration induced by CtBP2. ARF depletion or CtBP2 overexpression was associated with decreased PTEN expression and activation of the phosphatidylinositol 3-kinase pathway, and a phosphatidylinositol 3-kinase inhibitor blocked CtBP2-mediated cell migration. Thus, ARF can suppress cell migration by antagonizing CtBP2 and the phosphatidylinositol 3-kinase pathway, and these data may explain the increased aggressiveness of ARF-null tumors in mouse models.
authors.affiliation: Department of Cancer Biology, University of Massachusetts Medical School, 364 Plantation Street, Worcester, MA 01605, USA.
authors.forename: Seema
authors.initials: S
authors.lastname: Paliwal
authors.forename: Ramesh C
authors.initials: RC
authors.lastname: Kovi
authors.forename: Bharath
authors.initials: B
authors.lastname: Nath
authors.forename: Ya-Wen
authors.initials: YW
authors.lastname: Chen
authors.forename: Brian C
authors.initials: BC
authors.lastname: Lewis
authors.forename: Steven R
authors.initials: SR
authors.lastname: Grossman
mesh_terms: D000429:Alcohol Oxidoreductases; D015687:Cell Hypoxia / Q000502:physiology; D002465:Cell Movement / Q000235:genetics / Q000502:physiology*; D056970:Co-Repressor Proteins; D005136:Eye Proteins / Q000235:genetics / Q000378:metabolism*; D016147:Genes, Tumor Suppressor; D045325:HCT116 Cells; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D009243:NAD / Q000378:metabolism; D009419:Nerve Tissue Proteins; D010100:Oxygen / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D016364:Reading Frames; D014162:Transfection
chemical_list: D000429:Alcohol Oxidoreductases; D056970:Co-Repressor Proteins; D005136:Eye Proteins; D009243:NAD; D009419:Nerve Tissue Proteins; D010100:Oxygen; D019869:Phosphatidylinositol 3-Kinases; C421248:CTBP2 protein, human